World's Best Scientists 2026 revealed!
Armando Santoro

Armando Santoro

Award Badge
Medicine
Italy
2023

D-Index & Metrics

Medicine

D-Index
130
Citations
86090
World Ranking
2441
National Ranking
54

Armando Santoro publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Armando Santoro sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,254 publications — 97th percentile

97% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Armando Santoro D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Armando Santoro sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 130 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Italy Leader Award

Overview

Armando Santoro is affiliated with Humanitas University in Italy and has made contributions primarily in the field of Medicine, with a strong focus on Oncology. Their research covers several subfields including Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging, and Genetics.

The scientist's work frequently addresses topics related to cancer diagnosis, treatment, and immunotherapy. Key research topics include Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research, Advanced Breast Cancer Therapies, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.

Recent notable papers include:

  • "Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib" (2020, JAMA Oncology)
  • "Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer" (2021, Annals of Oncology)
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021, New England Journal of Medicine)
  • "Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial" (2020, The Lancet Oncology)
  • "PD-1 Blockade in Anaplastic Thyroid Carcinoma" (2020, Journal of Clinical Oncology)

The list of frequent co-authors highlights ongoing collaborative research efforts within the scientific community. These co-authors include Laura Giordano, Stéfania Bramanti, Rita De Sanctis, Carmelo Carlo-Stella, and Rosalba Torrisi.

Armando Santoro's work appears regularly in several publication venues, with a significant number of publications featured in Zenodo (CERN European Organization for Nuclear Research), Blood, Journal of Clinical Oncology, Cancers, and Annals of Oncology.

Best Publications

  • Sorafenib in Advanced Hepatocellular Carcinoma

    Josep M. Llovet;Sergio Ricci;Vincenzo Mazzaferro;Philip Hilgard

  • Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

    David Cunningham;Yves Humblet;Salvatore Siena;David Khayat

  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

    Mary E R O'Brien;N. Wigler;M. Inbar;R. Rosso

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

    Ghassan K. Abou-Alfa;Lawrence Schwartz;Sergio Ricci;Dino Amadori

  • Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

    Thomas Yau;Yoon Koo Kang;Tae You Kim;Anthony B. El-Khoueiry

  • Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

    Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani

  • Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

    Jordi Bruix;Jean Luc Raoul;Morris Sherman;Vincenzo Mazzaferro

  • Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

    Philippe Armand;Andreas Engert;Anas Younes;Michelle A Fanale

  • Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

    M. Van Glabbeke;A.T. van Oosterom;J.W. Oosterhuis;H. Mouridsen

  • Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

    A Santoro;T Tursz;H Mouridsen;Jaap Verweij

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study

    Armando Santoro;Lorenza Rimassa;Ivan Borbath;Bruno Daniele

  • Sorafenib: a review of its use in advanced hepatocellular carcinoma.

    Gillian M Keating;Armando Santoro

  • Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non–Small-Cell Lung Cancer Patients

    Federico Cappuzzo;Antonio Marchetti;Margaret Skokan;Elisa Rossi

  • Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

    Andrew X. Zhu;Masatoshi Kudo;Eric Assenat;Stéphane Cattan

  • SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma

    Andrew X. Zhu;Olivier Rosmorduc;T. R Jeffry Evans;Paul J. Ross

  • Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial

    Evan W Alley;Juanita Lopez;Armando Santoro;Anne Morosky

  • Identifying and Targeting ROS1 Gene Fusions in Non–Small Cell Lung Cancer

    Kurtis D. Davies;Anh T. Le;Mariana F. Theodoro;Margaret C. Skokan

  • Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD.

    S. Viviani;A. Santoro;G. Ragni;V. Bonfante

Frequent Co-Authors

Pier Luigi Zinzani
Pier Luigi Zinzani University of Bologna
Paolo Corradini
Paolo Corradini University of Milan
Camillo Porta
Camillo Porta University of Bari Aldo Moro
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Claudio Bordignon
Claudio Bordignon MolMed (Italy)
Umberto Tirelli
Umberto Tirelli National Institutes of Health
Arnon Nagler
Arnon Nagler Sheba Medical Center
Federico Cappuzzo
Federico Cappuzzo Azienda Unità Sanitaria Locale Della Romagna
Roberto Labianca
Roberto Labianca Mario Negri Institute for Pharmacological Research
Pinuccia Valagussa
Pinuccia Valagussa University of Louisville

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in healthcare careers beyond medicine, there are many affordable and flexible online degree options. Nursing is a popular pathway, and many wonder what is the cheapest online college for nursing?. Choosing a budget-friendly online nursing program can help minimize student debt while still gaining the necessary credentials.

For registered nurses looking to advance their education, there are most affordable accredited online rn to bsn programs that allow for career growth and increased earning potential. Those who already have experience in nursing and are interested in research or university-level teaching may want to explore online phd programs nursing, which offer flexible learning while reaching the highest levels of education in nursing.

If you hold a non-nursing bachelor’s degree, you might consider taking the accelerated route through cheapest direct entry msn programs. These programs fast-track students into advanced nursing roles, making a career change both practical and cost-effective. Exploring these online degrees expands your career prospects in the healthcare sector.

Best Scientists Citing Armando Santoro

Trending Scientists

Recently Published Articles